David J. Pisapia

TL;DR: A robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids is described, which promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options where standard clinical options have been exhausted.

TL;DR: In this article, the authors used chromosome conformation capture to demonstrate the specific association of an enhancer element, H, on chromosome 14 with multiple OR gene promoters on different chromosomes.

TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.

TL;DR: A computational platform that integrates the analysis of copy number variations and somatic mutations and unravels the landscape of in-frame gene fusions in glioblastoma provides insights into the pathogenesis of gliOBlastoma and highlights new targets for therapeutic intervention.

TL;DR: The GLICO model provides a system for modeling primary human GBM ex vivo and for high-throughput drug screening and shows that cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue.